News &amp; Updates

Results of a single-centre study in the UK have suggested that patients receiving systemic anticancer therapy for gastrointestinal (GI) cancers could continue their treatment during the COVID-19 pandemic.

GI cancer patients could continue therapy during COVID-19 pandemic

Extended-release viloxazine for ADHD in kids scores high in phase III trial

The investigational attention-deficit/hyperactivity disorder (ADHD) medication viloxazine extended-release, known as SPN-812, rapidly reduces symptoms in school-aged children with a tolerable safety profile, as shown in the results of a phase III trial.

Extended-release viloxazine for ADHD in kids scores high in phase III trial

YouTube videos of inhaler use omit key steps

Several videos for demonstrating Respimat Soft mist inhaler technique are available through YouTube, but some key steps have been omitted, according to a study, noting that comprehensive and repetitive patient education should be provided and supplemented with reputable online sources.

YouTube videos of inhaler use omit key steps

Chemo continues to benefit UTUC patients, updated POUT analysis shows

In an updated analysis of the phase III POUT* trial presented at ASCO GU 2021, peri-operative chemotherapy continued to improve disease-free survival (DFS) compared with surveillance in patients with upper tract urothelial cancer (UTUC).

Chemo continues to benefit UTUC patients, updated POUT analysis shows

Nivolumab + cabozantinib combo offers better QoL in advanced RCC

First-line treatment with nivolumab plus cabozantinib (NIVO+CABO) led to significantly better patient-reported quality of life (QoL) outcomes compared with sunitinib in patients with advanced renal cell carcinoma (RCC), according to an exploratory analysis of the CheckMate 9ER* trial presented at ASCO GU 2021.

Nivolumab + cabozantinib combo offers better QoL in advanced RCC

Enfortumab vedotin improves survival in previously treated advanced urothelial carcinoma

09 Mar 2021 by

Enfortumab vedotin improved overall survival (OS) compared with chemotherapy in patients with previously treated, locally advanced or metastatic urothelial carcinoma (UC), according to interim results of the phase III EV-301 study.

Enfortumab vedotin improves survival in previously treated advanced urothelial carcinoma

Concurrent checkpoint inhibitor therapy, radiation feasible in advanced melanoma

In patients with regionally advanced melanoma, concurrent administration of ipilimumab and radiation therapy is safe and beneficial, producing high response rates and converting unresectable disease to operable, as shown in a study.

Concurrent checkpoint inhibitor therapy, radiation feasible in advanced melanoma

SWOG 1500: PFS longer with cabozantinib than sunitinib in mPRCC

09 Mar 2021 by

Cabozantinib reduces the risk of disease progression or death by 40 percent compared with the current standard sunitinib in patients with metastatic papillary renal cell carcinoma (mPRCC) – a primary malignant tumour of the renal tubular epithelium – in the phase 2 SWOG 1500 study.

SWOG 1500: PFS longer with cabozantinib than sunitinib in mPRCC